CRISPR Therapeutics Vertex Pharmaceuticals: Better Buy in 2026
Investors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
Retirees benefit from selecting tax-efficient asset classes and optimized withdrawal sequencing. Learn which classes to favor and why.
23,930 articlesInvestors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
UiPath edges higher as investors monitor its agentic automation strategy ahead of earnings. This analysis breaks down...
Mastercard posts strong Q1 2026 results with rising services and margins, while PayPal signals a flat-to-down 2026. T...
Nvidia just landed a significant AI deal that could shift its growth trajectory. This article breaks down what invest...
Taiwan Semiconductor Manufacturing Co. reports a 36% quarterly sales increase, with June revenue surging as memory eq...
SoundHound AI aims to own the voice layer that connects users to services. This article builds a practical bull case ...
Kadant is navigating 2025 with a mix of packaging strength and manufacturing headwinds. This guide breaks down what t...
One stock stands out as an underrated artificial intelligence (ai) play that Wall Street expects to power higher. Her...
Anthropic’s dispute with the Pentagon over ethical uses triggers a contract cancellation and a supply chain risk desi...
Apple's pivot toward services could change how the stock is valued. This guide breaks down the thesis, risks, and a p...
Sonic Automotive and Penske Automotive Group post mixed Q4 results as tariff fears shape growth paths. EchoPark expan...
Waymo’s leadership argues that robotaxis will reframe work rather than eliminate it, highlighting maintenance, fleet ...